HSBC has reiterated its buy rating on Aster DM Healthcare with a target price of ₹680 per share. At the current market price of ₹641.10, the target implies an upside of about 6 percent.
The brokerage said the proposed merger of Aster with QCIL is on track to close by the fourth quarter of FY26. Both entities are focusing on operational ramp-up, with QCIL prioritising talent, technology and infrastructure (TTI) to drive operational efficiency and enhance profitability.
HSBC highlighted that sustained growth in Kerala and Bengaluru continues to be a key driver for Aster DM amid rising competition in the healthcare space. The brokerage believes that the ongoing integration and operational improvements should support long-term growth and margin expansion.
Disclaimer: The views and investment recommendations expressed above are those of HSBC. They do not represent the views of this publication. This article is for informational purposes only and is not investment advice.
